hemeonc.bib

@article{Wingard:2012:Blood:22692506,
  abstract = {Pulmonary nodules and nodular infiltrates occur frequently during treatment of hematologic malignancies and after hematopoietic cell transplantation. In patients not receiving active immunosuppressive therapy, the most likely culprits are primary lung cancer, chronic infectious or inactive granulomata, or even the underlying hematologic disease itself (especially in patients with lymphoma). In patients receiving active therapy or who are otherwise highly immunosuppressed, there is a wider spectrum of etiologies with infection being most likely, especially by bacteria and fungi. Characterization of the pulmonary lesion by high-resolution CT imaging is a crucial first diagnostic step. Other noninvasive tests can often be useful, but invasive testing by bronchoscopic evaluation or acquisition of tissue by one of several biopsy techniques should be performed for those at risk for malignancy or invasive infection unless contraindicated. The choice of the optimal biopsy technique should be individualized, guided by location of the lesion, suspected etiology, skill and experience of the diagnostic team, procedural risk of complications, and patient status. Although presumptive therapy targeting the most likely etiology is justified in patients suspected of serious infection while evaluation proceeds, a structured evaluation to determine the specific etiology is recommended. Interdisciplinary teamwork is highly desirable to optimize diagnosis and therapy.},
  added-at = {2012-12-17T23:57:18.000+0100},
  author = {Wingard, J R and Hiemenz, J W and Jantz, M A},
  biburl = {http://www.bibsonomy.org/bibtex/2c9291dab18c65795261bc7ecec3ea5e3/aorchid},
  doi = {10.1182/blood-2012-02-378976},
  interhash = {b4c13b782e030afcfb3548c942337966},
  intrahash = {c9291dab18c65795261bc7ecec3ea5e3},
  journal = {Blood},
  keywords = {fungal transplantation},
  month = aug,
  note = {made notes off of this article for fellows.},
  number = 9,
  pages = {1791-1800},
  pmid = {22692506},
  timestamp = {2012-12-17T23:57:18.000+0100},
  title = {How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation},
  url = {http://www.hubmed.org/display.cgi?uids=22692506},
  volume = 120,
  year = 2012
}

@ARTICLE{Winston2011,
  author = {Winston, Drew J. and Bartoni, Kathy and Territo, Mary C. and Schiller,
  Gary J.},
  title = {Efficacy, safety, and breakthrough infections associated with standard
	long-term posaconazole antifungal prophylaxis in allogeneic stem
	cell transplantation recipients.},
  year = {2011},
  language = {eng},
  volume = {17},
  number = {4},
  month = {Apr},
  pages = {507--515},
  doi = {10.1016/j.bbmt.2010.04.017},
  url = {http://dx.doi.org/10.1016/j.bbmt.2010.04.017},
  abstract = {Based on favorable results from randomized clinical trials, oral posaconazole
	has been approved for prophylaxis in neutropenic patients and stem
	cell transplantation (SCT) recipients. However, routine use of a
	prophylactic drug may yield different results than those from clinical
	trials. We collected data on the efficacy, safety, breakthrough infections,
	and antimicrobial resistance associated with standard long-term posaconazole
	prophylaxis in adult allogeneic SCT recipients at the UCLA Medical
	Center. Oral posaconazole (200 mg 3 times daily) was started on day
	1 after SCT and continued until day 100. After day 100, posaconazole
	was continued in patients who still required corticosteroids for
	prevention or treatment of graft-versus-host disease. From January
	2007 through December 2008, 106 consecutive patients received prophylactic
	posaconazole. Breakthrough invasive fungal infections on posaconazole
	occurred in 8 patients (7.5\%) within 6 months after SCT; 3 additional
	patients developed invasive fungal infection after discontinuation
	of prophylactic posaconazole. The infective organisms were Candida
	(8 cases), Aspergillus (2 cases), and Aspergillus plus Coccidioides
	immitis (1 case). There were no Zygomycetes infections. Only 2 (both
	Candida glabrata) of 9 infecting isolates tested were resistant to
	posaconazole (minimal inhibitory concentration >1 μg/mL). Mortality
	from invasive fungal infection occurred in 4 patients (3.7\%). Except
	for nausea in 9 patients, no clinical adverse event or laboratory
	abnormality could be attributed to posaconazole. Mean peak and trough
	plasma posaconazole concentrations were relatively low (<400 ng/mL)
	in neutropenic patients with oral mucositis and other factors possibly
	affecting optimal absorption of posaconazole. These results demonstrate
	that standard long-term oral posaconazole prophylaxis after allogeneic
	SCT is safe and associated with few invasive mold infections. However,
	breakthrough infections caused by posaconazole-susceptible organisms
	(frequently Candida) may occur at currently recommended prophylactic
	doses. Thus, strategies to improve posaconazole exposure, including
	the use of higher doses, administration with an acidic beverage,
	and restriction of proton pump inhibitors, need to be considered
	when using prophylactic posaconazole.},
  comment = {have paper reprint. See page 61 notebook 00002 for details.},
  groups = {public},
  institution = {Division of Hematology-Oncology, Department of Medicine, UCLA Medical
	Center, University of California-Los Angeles, CA 90095, USA. dwinston@mednet.ucla.edu},
  intrahash = {60d1bf30aaf4394d4c5a325ec75d6e7c},
  journal = {Biol Blood Marrow Transplant},
  keywords = {fungal, prophylaxis, transplantation},
  medline-pst = {ppublish},
  owner = {aorchid},
  pii = {S1083-8791(10)00198-9},
  pmid = {20460163},
  timestamp = {2012.07.10},
  username = {aorchid}
}

@ARTICLE{Fischer2009,
  author = {Fischer, S. A. and Avery, R. K. and , A. S. T Infectious Disease
	Community of Practice},
  title = {Screening of donor and recipient prior to solid organ transplantation.},
  year = {2009},
  language = {eng},
  volume = {9 Suppl 4},
  month = {Dec},
  pages = {S7--18},
  doi = {10.1111/j.1600-6143.2009.02888.x},
  url = {http://dx.doi.org/10.1111/j.1600-6143.2009.02888.x},
  comment = {not yet reviewed},
  file = {:ID_General/TransplantClinical/AmJTransplant.9s4.s7.pdf:PDF},
  institution = {Department of Medicine and Transplant Services, Rhode Island Hospital,
	The Warren Alpert Medical School of Brown University, Providence,
	RI, USA. sfischer@lifespan.org},
  journal = {Am J Transplant},
  keywords = {transplantation, prevention, donor},
  medline-pst = {ppublish},
  owner = {aorchid},
  pmid = {20070698},
  timestamp = {2012.12.19}
}

@ARTICLE{Luong2010a,
  author = {Luong, Me-Linh and Morrissey, Orla and Husain, Shahid},
  title = {Assessment of infection risks prior to lung transplantation.},
  year = {2010},
  language = {eng},
  volume = {23},
  number = {6},
  month = {Dec},
  pages = {578--583},
  doi = {10.1097/QCO.0b013e32833f9f93},
  url = {http://dx.doi.org/10.1097/QCO.0b013e32833f9f93},
  abstract = {Infections are major causes of morbidity and mortality after lung
	transplantation. Pretransplant evaluation can identify patients at
	risk of infectious complications and guide prophylactic strategies
	post transplantation. This review focuses on studies published from
	2006 to the present that relate to the assessment of risk of infection
	prior to lung transplantation.Pretransplant airways colonization
	with Pseudomonas, Burkholderia, nontuberculosis mycobacteria, Aspergillus
	and Scedosporium tend to recur after transplantation and cause disease
	in the lung allograft. Recently, colonization with Pseudomonas and
	Aspergillus species has been implicated in the subsequent development
	of allograft dysfunction. B. cenocepacia and Mycobacterium abscessus
	are particularly associated with poor outcomes after lung transplantation
	and are considered to be relative contra-indications to lung transplantation
	in many centers. Tuberculin skin test (TST) has limited value in
	predicting tuberculosis (TB) reactivation; however, in the absence
	of a better test, it remains the gold standard for screening patients
	with latent TB. Serologic screening for histoplasmosis and toxoplasmosis
	has limited value as these infections rarely occur after lung transplantation.Recurrence
	of pretransplant airway infection and reactivation of latent infection
	are potential sources of infection after lung transplantation. Prospective
	studies are needed to determine the efficacy of prophylactic antimicrobial
	strategies.},
  comment = {paper copy. See page 78 of notebook 00002},
  groups = {public},
  institution = {Multiorgan Transplant Infectious Diseases Division, Department of
	Medicine, University of Toronto, Toronto, Ontario, Canada.},
  intrahash = {821abb415cea79342114147c0996f716},
  journal = {Curr Opin Infect Dis},
  keywords = {transplantation, prevention, pseudomonas},
  medline-pst = {ppublish},
  owner = {aorchid},
  pmid = {20847696},
  timestamp = {2012.12.19},
  username = {aorchid}
}

@ARTICLE{Alexander2008a,
  author = {Alexander, B. D. and Petzold, E. W. and Reller, L. B. and Palmer,
	S. M. and Davis, R. D. and Woods, C. W. and Lipuma, J. J.},
  title = {Survival after lung transplantation of cystic fibrosis patients infected
	with Burkholderia cepacia complex.},
  year = {2008},
  language = {eng},
  volume = {8},
  number = {5},
  month = {May},
  pages = {1025--1030},
  doi = {10.1111/j.1600-6143.2008.02186.x},
  url = {http://dx.doi.org/10.1111/j.1600-6143.2008.02186.x},
  abstract = {Within the Burkholderia cepacia complex (Bcc), B. cenocepacia portends
	increased mortality compared with other species. We investigated
	the impact of Bcc infection on mortality and re-infection following
	lung transplant (LT). Species designation for isolates from Bcc-infected
	patients was determined using 16S rDNA and recA gene analyses. Of
	75 cystic fibrosis patients undergoing LT from September 1992 to
	August 2002, 59 had no Bcc and 16 had Bcc (including 7 B. cenocepacia)
	isolated in the year before LT. Of the latter, 87.5\% had Bcc recovered
	after transplantation, and all retained their pretransplant strains.
	Survival was 97\%, 92\%, 76\% and 63\% for noninfected patients;
	89\%, 89\%, 67\% and 56\% for patients infected with Bcc species
	other than B. cenocepacia; and 71\%, 29\%, 29\% and 29\% for patients
	with B. cenocepacia (p = 0.014) at 1 month, 1 year, 3 years and 5
	years, respectively. Patients infected with B. cenocepacia before
	transplant were six times more likely to die within 1 year of transplant
	than those infected with other Bcc species (p = 0.04) and eight times
	than noninfected patients (p < 0.00005). Following LT, infection
	with Bcc species other than B. cenocepacia does not significantly
	impact 5-year survival whereas infection with B. cenocepacia pretransplant
	is associated with decreased survival.},
  comment = {not reviewed yet.},
  groups = {public},
  institution = {Division of Infectious Diseases and International Health, Department
	of Medicine, Duke University School of Medicine, Durham, NC, USA.
	alexa011@mc.duke.edu},
  intrahash = {42c8de5f387baa4b72a6f12d6614faad},
  journal = {Am J Transplant},
  keywords = {transplantation, pneumonia, pseudomonas},
  medline-pst = {ppublish},
  owner = {aorchid},
  pii = {AJT2186},
  pmid = {18318775},
  timestamp = {2012.12.19},
  username = {aorchid}
}

@ARTICLE{Boussaud2008,
  author = {Boussaud, V. and Guillemain, R. and Grenet, D. and Coley, N. and
	Souilamas, R. and Bonnette, P. and Stern, M.},
  title = {Clinical outcome following lung transplantation in patients with
	cystic fibrosis colonised with Burkholderia cepacia complex: results
	from two French centres.},
  year = {2008},
  language = {eng},
  volume = {63},
  number = {8},
  month = {Aug},
  pages = {732--737},
  doi = {10.1136/thx.2007.089458},
  url = {http://dx.doi.org/10.1136/thx.2007.089458},
  abstract = {Infection with Burkholderia cepacia complex (BCC) is a life threatening
	complication of cystic fibrosis (CF), often seen as a contraindication
	for lung transplantation.A long term retrospective study was conducted
	of all patients with CF undergoing lung transplants from January
	1990 to October 2006 in two French centres allowing transplantation
	in patients colonised with BCC.22 of the 247 lung transplant patients
	with CF were infected with BCC (B. cenocepacia genomovar III (n =
	8), B. multivorans genomovar II (n = 11), B. vietnamiensis genomovar
	V (n = 2) and B. stabilis genomovar IV (n = 1)). BCC colonisation
	was not associated with any significant excess mortality (HR 1.5,
	95\% CI 0.7 to 3.2; p = 0.58). However, early mortality rates tended
	to be higher in the BCC group than in the non-BCC group (3 month
	survival: 85\% vs 95\%, respectively; log rank p = 0.05). Univariate
	analysis showed that the risk of death was significantly higher for
	the eight patients infected with B. cenocepacia than for the other
	14 colonised patients (HR 3.2, 95\% CI 1.1 to 5.9; p = 0.04). None
	of the other risk factors tested-primary graft failure, late extubation,
	septicaemia-had a significant effect. The 5 year cumulative incidence
	rate of bronchiolitis obliterans syndrome was not significantly higher
	in the BCC group than in the non-BCC group (38\% vs 24\%, respectively;
	p = 0.35).Our results suggest that BCC infection with a non-genomovar
	III organism may not be associated with excess mortality after lung
	transplantation in patients with CF and should not be seen as sufficient
	reason to exclude lung transplantation. However, colonisation with
	B. cenocepacia remains potentially detrimental.},
  comment = {not reviewed yet.},
  groups = {public},
  institution = {Pôle cardio-thoracique, AP-HP, HEGP, Paris, France. veronique.boussaud@egp.aphp.fr},
  intrahash = {9cc27bd995bcb7650a2f5b9bc99f9eca},
  journal = {Thorax},
  keywords = {transmission, pneumonia, pseudomonas},
  medline-pst = {ppublish},
  owner = {aorchid},
  pii = {thx.2007.089458},
  pmid = {18408050},
  timestamp = {2012.12.19},
  username = {aorchid}
}

@ARTICLE{RefWorks:2938,
  author = {J. Gottlieb and F. Mattner and H. Weissbrodt and M. Dierich and T.
	Fuehner and M. Strueber and A. Simon and T. Welte},
  title = {Impact of graft colonization with gram-negative bacteria after lung
	transplantation on the development of bronchiolitis obliterans syndrome
	in recipients with cystic fibrosis},
  year = {2009},
  language = {eng},
  volume = {103},
  number = {5},
  month = {May},
  pages = {743-749},
  note = {JID: 8908438; 2008/06/02 [received]; 2008/08/21 [revised]; 2008/11/18
	[accepted]; 2008/12/30 [aheadofprint]; ppublish},
  doi = {10.1016/j.rmed.2008.11.015},
  url = {http://dx.doi.org/10.1016/j.rmed.2008.11.015},
  abstract = {Bronchiolitis obliterans syndrome (BOS) represents the leading cause
	of late mortality after lung transplantation (LTx). Cystic fibrosis
	(CF) patients frequently show airway colonization with gram-negative
	bacteria (GNB) both before and after LTx. Graft colonization with
	GNB and its relevance towards BOS development were investigated in
	a CF population after LTx. Adult CF patients receiving LTx and surviving
	at least 6 months were included in this prospective observational
	study between 1/1/2002 and 30/6/2006 in a single center and followed
	until 31/3/2007. Pre- and post-LTx respiratory culture samples were
	compared for the presence of identical GNB. BOS-free survival was
	compared in colonized and non-colonized patients. Fifty-nine adult
	CF patients with a median age at LTx of 25.5 (18-49) years were included
	and had a median follow-up of 966 (128-1889) days. Seven patients
	(15%) demonstrated immediate eradication of GNB in lower respiratory
	tract samples. A further 18 patients (34%) demonstrated transient
	colonization. Thirty-four recipients had further positive samples
	after LTx. Eighteen patients (31%) developed BOS >or=stage 1, 508
	(114-1167) days after LTx. Freedom of graft colonization with pseudomonads
	was independently associated with less frequent development of BOS
	(p=0.006). Persistent graft colonization with pseudomonads increases
	the prevalence of BOS after LTx in CF patients. A significant proportion
	of post-LTx CF patients demonstrates subsequent GNB eradication during
	later follow-up and this may have a protective role against development
	of BOS. Strategies to eradicate airway colonization or reduce bacterial
	load may prevent BOS in CF patients after LTx.},
  comment = {see page 27 of notebook 00002. Good one. Pseudomonas (and some other
	GNR) persistent colonization predict BOS, as does AR.},
  groups = {public},
  intrahash = {d54b13193a0ece67862080f0537e67a8},
  isbn = {1532-3064; 0954-6111},
  journal = {Resp Med},
  keywords = {pseudomonas, bos, transplantation, rejection},
  owner = {aorchid},
  timestamp = {2012.02.09},
  username = {aorchid}
}

@ARTICLE{RefWorks:2926,
  author = {D. Hadjiliadis and M. P. Steele and C. Chaparro and L. G. Singer
	and T. K. Waddell and M. A. Hutcheon and R. D. Davis and D. E. Tullis
	and S. M. Palmer and S. Keshavjee},
  title = {Survival of lung transplant patients with cystic fibrosis harboring
	panresistant bacteria other than Burkholderia cepacia, compared with
	patients harboring sensitive bacteria},
  year = {2007},
  language = {eng},
  volume = {26},
  number = {8},
  month = {Aug},
  pages = {834-838},
  note = {JID: 9102703; 0 (Anti-Bacterial Agents); 2006/12/19 [received]; 2007/04/02
	[revised]; 2007/05/28 [accepted]; 2007/07/12 [aheadofprint]; ppublish},
  abstract = {BACKGROUND: The impact of panresistant bacteria, other than Burkholderia
	cepacia, on the survival after lung transplantation in patients with
	cystic fibrosis (CF) remains controversial. METHODS: To determine
	the impact of panresistant bacteria in CF patients on survival after
	lung transplantation a retrospective multicenter study was performed.
	All lung transplant recipients with a pre-transplant diagnosis of
	CF, at the University of Toronto (n = 53) and Duke University (n
	= 50), were included. Patients were included in the panresistant
	group if at least one specimen isolated from their respiratory secretions
	grew bacteria resistant or intermediate to all classes of antibiotics
	tested. Patients with sensitive or resistant B cepacia were excluded
	because of its adverse impact upon post-transplant survival. RESULTS:
	Forty-five of 103 (43.7%) patients harbored panresistant bacteria
	(43 had Pseudomonas aeruginosa, 1 had Stenotrophomonas maltophilia,
	and 1 had Achromobacter xylosoxidans). According to log-rank test,
	there was decreased survival in patients with panresistant bacteria
	compared to patients with sensitive bacteria (survival: 91.1 +/-
	4.2% vs 98.3 +/- 1.7% at 3 months; 88.6 +/- 4.8% vs 96.6 +/- 2.4%
	at 1 year; 63.2 +/- 8.6% vs 90.7 +/- 4.0% at 3 years; 58.3 +/- 9.2%
	vs 85.6 +/- 5.2% at 5 years; p = 0.016). The results did not differ
	significantly between the two centers. Both groups had similar or
	better survival than CF patients as reported by the United Network
	of Organ Sharing (UNOS) registry (1-year, 86.0%; 3 years, 65.4%;
	5 years, 49.6%). CONCLUSIONS: Patients with CF harboring panresistant
	bacteria have slightly decreased survival, but their survival is
	comparable to the results published by the UNOS registry.},
  comment = {see page 26 of notebook 00002. For CF lung transplant at Toronto and
	Duke transplanted 1992-2001.},
  groups = {public},
  intrahash = {5a0d6b493f82de491e33fdbe6ff9ad9d},
  isbn = {1557-3117; 1053-2498},
  journal = {J Heart Lung Transpl},
  keywords = {transplantation, pseudomonas, drugresistance, prevention},
  owner = {aorchid},
  timestamp = {2012.02.09},
  username = {aorchid}
}

@ARTICLE{Steinbach2012,
  author = {Steinbach, W J and Marr, K A and Anaissie, E J and Azie, N and Quan,
	S P and Meier-Kriesche, H U and Apewokin, S and Horn, D L},
  title = {Clinical epidemiology of 960 patients with invasive aspergillosis
	from the PATH Alliance registry},
  year = {2012},
  volume = {65},
  number = {5},
  month = {Nov},
  pages = {453-464},
  doi = {10.1016/j.jinf.2012.08.003},
  url = {http://www.hubmed.org/display.cgi?uids=22898389},
  abstract = {The study investigated the epidemiology and outcome of invasive aspergillosis
	(IA), an important cause of morbidity and mortality in immunocompromised
	patients.Cases of proven/probable IA from the Prospective Antifungal
	Therapy Alliance (PATH Alliance(�)) registry - a prospective surveillance
	network comprising 25 centers in the United States and Canada that
	collected data on invasive fungal infections from 2004 to 2008 -
	were analyzed with respect to clinical outcome.Nine hundred and sixty
	patients with IA were enrolled, the most frequent underlying disease
	being hematologic malignancy (n=464 [48.3%]). Two hundred and eighty
	patients (29.2%) received solid organ transplant; 268 patients (27.9%)
	underwent hematopoietic stem cell transplantation. Identified isolates
	included Aspergillus fumigatus (72.6%), Aspergillus flavus (9.9%),
	Aspergillus niger (8.7%) and Aspergillus terreus (4.3%). The lung
	was most frequently affected. Following diagnosis, 47% patients received
	monotherapy - voriconazole (70%), an amphotericin B formulation (13.8%),
	or an echinocandin (10.5%) - while 279 patients (29%) received combination
	therapy. Twelve-week overall survival was 64.4%.In this series of
	patients with IA, the lung was the predominant focus of infection,
	A. fumigatus was the major species isolated, and overall survival
	appeared slightly improved compared with previous reports.},
  file = {:ID_General/TransplantClinical/JInfect.65.453.pdf:PDF},
  journal = {J Infect},
  keywords = {fungal, drug, transplantation},
  owner = {aorchid},
  pmid = {22898389},
  timestamp = {2013.03.22}
}

@ARTICLE{Singh2013,
  author = {Singh, Nina and Suarez, Jose F. and Avery, Robin and Lass-Flörl,
	Cornelia and Geltner, Christian and Pasqualotto, Alessandro C. and
	{Marshall Lyon}, G. and Barron, Michelle and Husain, Shahid and Wagener,
	Marilyn M. and Montoya, Jose G.},
  title = {Risk factors and outcomes in lung transplant recipients with nodular
	invasive pulmonary aspergillosis.},
  year = {2013},
  language = {eng},
  volume = {67},
  number = {1},
  month = {Jul},
  pages = {72--78},
  doi = {10.1016/j.jinf.2013.03.013},
  url = {http://dx.doi.org/10.1016/j.jinf.2013.03.013},
  abstract = {Whether nodular lesions have specific risk-factors or influence outcomes
	in lung transplant recipients with invasive aspergillosis, is not
	fully known.The study population consisted of 64 consecutive lung
	transplant recipients with proven or probable invasive aspergillosis.
	Nodules, with or without halo/air crescent-sign were considered nodular
	presentations. Outcomes assessed were response rate (successful versus
	unsuccessful outcome) and all-cause mortality at 12 weeks.Overall,
	34 patients had nodular and 30 had non-nodular lesions. Presence
	of nodular lesions was less likely to be associated with renal failure
	at baseline (adjusted OR 0.21, 95\% CI, 0.04-0.97, p = 0.047), CMV
	infection (adjusted OR 0.18, 95\% CI 0.04-0.75, p = 0.019) and receipt
	of antifungal prophylaxis (adjusted OR 0.22, 95\% CI, 0.06-0.88,
	p = 0.032). Successful outcome and mortality rates in the study patients
	were 64.0\% (41/64) and 25.0\% (16/64), respectively. Nodular aspergillosis
	was associated with significantly higher successful outcome (adjusted
	OR 3.35, 95\% CI, 1.06-10.54, p = 0.039) and lower mortality at 12
	weeks (adjusted OR 0.20, 0.05-0.78, p = 0.021).Lung transplant recipients
	with nodular lesions due to invasive aspergillosis had better outcomes
	than those without such lesions.},
  comment = {nodular disease had better outcome. Non-nodular disease associated
	with renal failure, CMV infection and prior vori prophylaxis. Successful
	outcome in 64% and 75% survival overall. But 12 week all-cause mortality
	23% in nodular, 54% non-nodular. Median time to invasive disease
	was 423 days post-transplant. 53% had nodular disease.},
  file = {:ID_General/TransplantClinical/JInfect.67.72.pdf:PDF},
  institution = {University of Pittsburgh, Pittsburgh, PA 15240, USA. nis5@pitt.edu},
  journal = {J Infect},
  keywords = {Antifungal Agents, therapeutic use; Female; Humans; Invasive Pulmonary
	Aspergillosis, drug therapy/mortality/pathology; Lung Transplantation;
	Lung, pathology; Male; Middle Aged; Risk Factors; Survival Analysis;
	Transplantation; Treatment Outcome},
  medline-pst = {ppublish},
  owner = {aorchid},
  pii = {S0163-4453(13)00069-8},
  pmid = {23567625},
  timestamp = {2014.03.25}
}